- Home
- GGR vs AARD Comparison
GGR vs AARD Comparison
Compare GGR & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GGR | AARD |
|---|---|---|
| Founded | 2011 | 2017 |
| Country | Taiwan | United States |
| Employees | 1416 | 40 |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.3M | 85.7M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | GGR | AARD |
|---|---|---|
| Price | $4.01 | $4.06 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $15.29 |
| AVG Volume (30 Days) | 10.4K | ★ 156.3K |
| Earning Date | 05-21-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.07 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.24 | $3.35 |
| 52 Week High | $6.21 | $17.94 |
Technical Indicators
Market Signals| Indicator | GGR | AARD |
|---|---|---|
| Relative Strength Index (RSI) | 49.79 | 38.43 |
| Support Level | $3.93 | $3.35 |
| Resistance Level | $4.33 | $4.39 |
| Average True Range (ATR) | 0.20 | 0.58 |
| MACD | -0.02 | -0.14 |
| Stochastic Oscillator | 40.30 | 6.06 |
Price Performance
Historical ComparisonAbout GGR Gogoro Inc.
Gogoro Inc is focused on eliminating the barriers to electric fuel adoption to bring swappable electric power within reach of every urban rider. Its battery swapping technology compromises an interoperable platform that seamlessly integrates a comprehensive ecosystem of hardware, software, and services, which consists of Gogoro Smart Batteries, GoStations, Gogoro Network Software & Battery Management Systems, Smartscooter, and related components and kits. Geographical presence in Taiwan and Other countries, majority of its revenue comes from Tiwan.
About AARD Aardvark Therapeutics Inc.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.